Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Pyrrolo[2,3 d]pyrimidine. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel synthetic route for 4-chloropyrrolo pyrimidine ensures safety and high yield. Ideal for reliable pharmaceutical intermediate supplier seeking cost reduction and scale-up.
Patent CN101830904B reveals a safer 4-step synthesis for 4-chloropyrrolo[2,3-d]pyrimidine, offering high purity and cost reduction in pharmaceutical intermediate manufacturing.
Advanced two-step synthesis of 4-chloro-7H-pyrrolo[2,3-d]pyrimidine offering high purity and cost efficiency for JAK inhibitor manufacturing supply chains.
Patent CN112979662A details a transition-metal-free acetoxylation route. This breakthrough offers cost reduction in pharmaceutical intermediate manufacturing with high purity.
Novel 4-step synthesis of 4-chloropyrrolo[2,3-d]pyrimidine avoiding sodium hydride. High purity 98%+ yields for kinase inhibitor manufacturing.
Novel patent CN105622616A offers high-yield synthesis for 4-chloropyrrolo pyrimidine. Enhances supply chain reliability and reduces manufacturing complexity for global buyers.
Patent CN1213998C details a novel route for antifolate intermediates using stable sulfonic acid salts, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN114957262A details a Pd-catalyzed C-H activation method for deazapurines, offering high regioselectivity and mild conditions for scalable API intermediate production.
Novel copper-catalyzed route for Rabociclib intermediate offers high purity and cost-effective manufacturing solutions for pharmaceutical supply chains globally.
Novel nickel-catalyzed route for Ruxolitinib key intermediate. Reduces cost, eliminates palladium, ensures high purity for API manufacturing.
Patent CN102633802B details a scalable 3-step route for 2-chloro-7H-pyrrolo[2,3-d]pyrimidine, offering significant cost reduction and simplified purification for API manufacturing.
Patent CN106749259B reveals a metal-free synthetic route for CDK4/6 inhibitor intermediates, offering significant cost reduction and supply chain reliability for global pharmaceutical manufacturers.
Patent CN113292563B reveals a mild Pd-catalyzed C-H bisacetoxylation method for pyrrolo[2,3-d]pyrimidines, offering reliable pharmaceutical intermediate supply and cost reduction.
Solve high-cost palladium catalyst issues in treacli production. 4-step route with 87.6% yield & 99.4% purity. Scale to 100MT/yr for oncology applications.